Emergence of novel SARS-CoV-2 variants and co-mutations in India

A new study has uncovered genetic changes in a group of similar severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants in India.

The researchers write:

"We believe that our report is one of the few studies that aim to provide a comprehensive picture of the evolutionary dynamics and co-mutations patterns of the SARS-CoV-2 strains prevalent within Indian population throughout the year 2020."

The study "Genomic surveillance and phylodynamic analyses reveal the emergence of a novel mutation and co-mutation patterns within SARS-CoV2 variants prevalent in India" is available as a preprint on the bioRxiv* server, while the article undergoes peer review.

How they did it

The researchers performed genomic surveillance of 54 samples positive for SARS-CoV-2 from Kolkata — the capital of West Bengal state of India. Patients ranged from 6-88 years with an overall male to female ratio of 1.7.

The samples were collected from August 2020 to October 2020 (Term3) and comprise all SARS-CoV-2 genome sequences in West Bengal except for one.

The team notes the Term3 genetic sequences are different from India's because they show a higher amount of 'O' clade and 20A clade.

The Term3 sequences also differed from SARS-CoV-2 genetic sequences collected from April 2020 to July 2020 (Term 2). In Term2, the West Bengal region had an 82% higher amount of 'G' and 83% higher amount of 20A clade distribution than the other states of India. They indicate the viral clades in West Bengal are evolving slowly.

Using the GSAID database, they analyzed their samples to the genomic sequences in other continents. And except North America and Europe, all other continents had a prevalence of the GR clade in the middle and end of 2020. While North America did not show a GR prevalence, they showed a higher frequency of GH clade. Europe showed more increases of the GV clade of SARS-CoV-2 in Europe at the end of the year.

Frequent mutations, co-mutations and their association with disease severity in India. A. Most frequent 5 mutations and 3 co-mutation patterns in India. B. Most frequent 5 mutations and 3 co-mutations in major clades of India. Clade defining mutations are excluded in the bar plot. C. Most frequent 5 mutations and 3 co-mutations in different types of patients. Different color codes are used for specific co-mutation network motifs. Network motifs were sorted and ranked exclusively.
Frequent mutations, co-mutations and their association with disease severity in India. A. Most frequent 5 mutations and 3 co-mutation patterns in India. B. Most frequent 5 mutations and 3 co-mutations in major clades of India. Clade defining mutations are excluded in the bar plot. C. Most frequent 5 mutations and 3 co-mutations in different types of patients. Different color codes are used for specific co-mutation network motifs. Network motifs were sorted and ranked exclusively.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Emergence of mutations during the pandemic

Next, the researchers tracked the evolutionary changes of SARS-CoV-2 in other areas in India. Genomic surveillance from viral samples in Indian patients showed the GR and 20B clade were more prevalent in India.

When looking at the variation of co-mutations across Indian states and union territories, the researchers observed the emergence of non-clade defining mutations during Term2 and Term3. These results were comparable to the beginning of the pandemic (Term1). Unique combinations of these mutations were reported more frequently toward the end of 2020.

Specifically, in Term 2, India's states such as Telangana, Maharashtra, and Karnataka showed five or more co-mutations. At the same time, the West Bengal area and Gujarat had SARS-CoV-2 strains with less than five co-mutations.

By Term 3, there were more sequences of Telangana and Maharashtra with higher co-mutating residues than those of West Bengal. The rise of distinct mutations may be associated with a significant increase of coronavirus cases in Maharashtra and Karnataka compared to West Bengal and Gujarat during 'Term2' and 'Term3'.

"Hence, the higher number co-mutations in those two states could be associated with higher infectivity of the strains prevalent there."

Mutations correlated with severity of disease

The team used their genomic surveillance data to assess how mutations affected the severity of COVID-19 illness. They could use 806 of 3,277 sequences as it included a patient's COVID-19 status and if they were deceased, symptomatic, mild, and asymptomatic.

All sequences showed the D614G and NSP12 mutations. However, people who had symptomatic COVID-19 infection or who died from COVID-19 were more likely to show more NS9b(P10S), N(P13L), NSP12(A97V), and NSP3(T1198K) mutations than patients who were asymptomatic.

There was also a co-mutation triad in [NSP6(L37F)-NSP12(P323L)-Spike(D614G)] in patients who are deceased or who have mild or symptomatic COVID-19 infection.

Among 5 mutations in deceased and symptomatic patients, 3 mutations were observed in mild infection, with only the NSP6(L37F) mutation appearing in asymptomatic patients.

The co-mutation network was shown in 51% of patients with asymptomatic disease and 20.41% of mild infections. However, the co-mutation network was not seen in symptomatic cases and the deceased. New co-mutation networks were noted across time in different clades and states of India.

The researchers suggest specific mutations and unique combinations of SARS-CoV-2 mutations are correlated with disease severity based on the results.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • Apr 7 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Jocelyn Solis-Moreira

Written by

Jocelyn Solis-Moreira

Jocelyn Solis-Moreira graduated with a Bachelor's in Integrative Neuroscience, where she then pursued graduate research looking at the long-term effects of adolescent binge drinking on the brain's neurochemistry in adulthood.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Solis-Moreira, Jocelyn. (2023, April 07). Emergence of novel SARS-CoV-2 variants and co-mutations in India. News-Medical. Retrieved on October 10, 2024 from https://www.news-medical.net/news/20210329/Emergence-of-novel-SARS-CoV2-variants-and-co-mutations-in-India.aspx.

  • MLA

    Solis-Moreira, Jocelyn. "Emergence of novel SARS-CoV-2 variants and co-mutations in India". News-Medical. 10 October 2024. <https://www.news-medical.net/news/20210329/Emergence-of-novel-SARS-CoV2-variants-and-co-mutations-in-India.aspx>.

  • Chicago

    Solis-Moreira, Jocelyn. "Emergence of novel SARS-CoV-2 variants and co-mutations in India". News-Medical. https://www.news-medical.net/news/20210329/Emergence-of-novel-SARS-CoV2-variants-and-co-mutations-in-India.aspx. (accessed October 10, 2024).

  • Harvard

    Solis-Moreira, Jocelyn. 2023. Emergence of novel SARS-CoV-2 variants and co-mutations in India. News-Medical, viewed 10 October 2024, https://www.news-medical.net/news/20210329/Emergence-of-novel-SARS-CoV2-variants-and-co-mutations-in-India.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study reveals population-wide immune setpoint for SARS-CoV-2 antibodies